Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Luciano Nicosia
Observed name:
NICOSIA, LUCIANO
Institution:
Cancer Research UK Manchester Institute
Observed institutions:
University of Manchester,
Cancer Research UK Manchester Institute,
Cancer Research UK Manchester Centre,
European Institute of Oncology
ORCID:
0000-0003-3016-931X
Observed ORCID:
0000-0003-3016-931X
OpenAlex ID:
A5037073267
Works
18
Awards
1
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
2023
·
Luciano Nicosia
, Gary J. Spencer
, et al.
·
Cancer Cell
·
139
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation
2020
·
Roberto Ravasio
, Elena Ceccacci
, et al.
·
Science Advances
·
97
PDF
PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin
2020
·
Daniele Musiani
, Roberto Giambruno
, et al.
·
Cell Reports
·
75
PDF
LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response
2021
·
Stefania Faletti
, Daniela Osti
, et al.
·
Science Translational Medicine
·
49
PDF
Chromatin proteomics reveals novel combinatorial histone modification signatures that mark distinct subpopulations of macrophage enhancers
2017
·
Monica Soldi
, Tommaso Mari
, et al.
·
Nucleic Acids Research
·
38
PDF
Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML
2021
·
Luciano Nicosia
, Francesca Ludovica Boffo
, et al.
·
Oncogene
·
32
PDF
HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block
2022
·
Alba Maiques-Diaz
, Luciano Nicosia
, et al.
·
Oncogene
·
14
PDF
ProMetheusDB: An In-Depth Analysis of the High-Quality Human Methyl-proteome
2022
·
Enrico Massignani
, Roberto Giambruno
, et al.
·
Molecular & Cellular Proteomics
·
11
PDF
Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma
2022
·
Luciano Nicosia
, Nigel Brooks
, et al.
·
Blood
·
6
Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia
2022
·
Luciano Nicosia
, Gary J Spencer
, et al.
·
Blood
·
5
Native Chromatin Proteomics (N-ChroP) to Characterize Histone Post-translational Modification (PTM) Combinatorics at Distinct Genomic Regions
2021
·
Luciano Nicosia
, Tiziana Bonaldi
·
Methods in molecular biology
·
2
Mass Spectrometry and Epigenetics
2017
·
Luciano Nicosia
, Roberta Noberini
, et al.
·
Springer eBooks
·
2
Mass Spectrometry and Epigenetics
2019
·
Luciano Nicosia
, Roberta Noberini
, et al.
·
Springer eBooks
·
1
SRSF2 mutation-induced CHD8 exon skipping represents a novel pathogenic mediator and therapeutic dependence in chronic myelomonocytic leukemia (CMML)
2025
·
Yu-Hung Wang
, Kristian Gurashi
, et al.
·
Blood
Prognostic and Therapeutic Implications of TP53 expression in Chronic Myelomonocytic Leukaemia: Results of a Multicentre Study
2023
·
Yu-Hung Wang
, Chien-Chin Lin
, et al.
·
Blood
P-190 Potent pre-clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma
2023
·
Kris Frese
, Luciano Nicosia
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
S171: Higher Mdmx Expression Was Associated With Hypomethylating Agent Resistance and Worse Survival in Myelodysplastic Syndrome Patients, Inferring It a Potential Therapeutic Target
2023
·
Yu-Hung Wang
, Chien-Chin Lin
, et al.
·
HemaSphere
Chromatin Proteomics Dissects the Mechanism of Action of Lsd1 Inhibitors in Acute Promyelocytic Leukemia
2020
·
NICOSIA, LUCIANO
·
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano)
Show more works
View as search
Works count:
18
Citation count:
480
H-index:
8
I10-index:
8
Year
Topic
Type